Meeting
2016 ASCO Annual Meeting
Enhanced efficacy and safety of Her2-targeted chimeric antigen receptor (CAR) T cells using MyD88/CD40 costimulation and iCaspase-9 suicide switch.
Authors
Aaron E Foster
Bellicum Pharmaceuticals, Houston, TX
Aaron E Foster , Jeannette Crisostomo , Peter Chang , Pei-Yi Lin , Aruna Mahendravada , An Lu , Mariam Khalil , Sunandan Saha , Kevin Mark Slawin , David M Spencer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Cellular Immunotherapy
Citation
J Clin Oncol 34, 2016 (suppl; abstr 3050)
DOI
10.1200/JCO.2016.34.15_suppl.3050
Abstract #
3050
Poster Bd #
372
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase Ib study of endogenous T cell therapy using SLC45A2-specific CD8 T cells for patients with metastatic uveal melanoma.
First Author: Suzanne Phillips
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Antigen-dependent costimulation to improve T-cell therapy for cancer.
First Author: Christopher C. DeRenzo
Poster
2016 Genitourinary Cancers Symposium
Inducible MyD88/CD40 to allow rimiducid-dependent activation for control of proliferation and survival of chimeric antigen receptor (CAR) T cells targeting prostate stem cell antigen (PSCA).
First Author: Kevin Mark Slawin
Poster
2024 ASCO Annual Meeting
Phase IIA study of high-affinity TCR-T (TAEST16001) targeting NY-ESO-1 in soft tissue sarcoma.
First Author: Jiayong Liu